Eli Lilly dishes out first milestone payment for Alzheimer's deal; ADC Therapeutics, Viela Bio set terms for IPO
→ With others shying away from the Alzheimer’s field after the many clinical implosions and disasters, Eli Lilly is still chugging along …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
